drugset / Trial / NCT01876251

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

NCT01876251

Phase 1 Terminated 30 enrolled Pfizer
Open-labelTreatment

Summary

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Timeline

Start
2013-11-04
Primary completion
2015-12-24
Completion
2015-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Docetaxel Small molecule 100 mg/m2 Intravenous
Subject Nirogacestat Small molecule 10 mg Oral
Subject Nirogacestat Small molecule 50 mg Oral
Subject Nirogacestat Small molecule 100 mg Oral

Indications